Group 1 - The company has completed the review of its generic drug, Hydrobromide Sitagliptin Tablets, on September 12, but has not issued any announcement regarding this progress [1] - The company faced scrutiny due to a regulatory letter received for the illegal increase in shares by the actual controller's concerted actors, highlighting issues with information disclosure [1] - The company responded on September 17, stating that the generic drug is still undergoing supplementary pharmaceutical data review and has not yet completed the review process, assuring compliance with regulatory disclosure obligations [1]